ReviewTranslational research : the journal of laboratory and clinical medicine2016
Inflammatory targets of therapy in sickle cell disease.
Review in Translational research : the journal of laboratory and clinical medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Quantifying dilated perivascular spaces in children with sickle cell disease.Pediatric blood & cancer · 2024Trial
- Effect of Gum Arabic (Acacia senegal) on C-reactive protein level among sickle cell anemia patients.BMC research notes · 2020Trial
- A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study.American journal of hematology · 2018Trial
- Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.British journal of haematology · 2017Trial
- A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.Blood · 2016Trial
- Plasma oxylipins in children with sickle cell disease: Associations with biomarkers of inflammation and endothelial activation.Prostaglandins, leukotrienes, and essential fatty acids · 2025Article
- Statins and adhesion molecules: a review of a novel pleiotropic property of statins.Immunologic research · 2025Review
- Hydroxyurea Therapy and Sleep-Disordered Breathing in Children With Sickle Cell Disease.Pediatric blood & cancer · 2025Article
- Therapeutics for sickle cell disease intravascular hemolysis.Frontiers in physiology · 2024Review
- Role of Macrophages in Sickle Cell Disease Erythrophagocytosis and Erythropoiesis.International journal of molecular sciences · 2023Review
- Nrf2 Activation With CDDO-Methyl Promotes Beneficial and Deleterious Clinical Effects in Transgenic Mice With Sickle Cell Anemia.Frontiers in pharmacology · 2022Article
- Soluble MD-2 and Heme in Sickle Cell Disease Plasma Promote Pro-Inflammatory Signaling in Endothelial Cells.Frontiers in immunology · 2021Article
- Article
- Updated mechanisms underlying sickle cell disease-associated pain.Neuroscience letters · 2019Review
- Emerging disease-modifying therapies for sickle cell disease.Haematologica · 2019Review
- Relationship of Omega-3 fatty acids DHA and EPA with the inflammatory biomarker hs-CRP in children with sickle cell anemia.Prostaglandins, leukotrienes, and essential fatty acids · 2019Article
- Modulating NRF2 in Disease: Timing Is Everything.Annual review of pharmacology and toxicology · 2019Review
- New insights into the pathophysiology and development of novel therapies for sickle cell disease.Hematology. American Society of Hematology. Education Program · 2018Review
- Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease.Pain · 2018Article
- Clinical and genetic factors are associated with pain and hospitalisation rates in sickle cell anaemia in Cameroon.British journal of haematology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Sickle cell disease (SCD) is a monogenic globin disorder characterized by the production of a structurally abnormal hemoglobin (Hb) variant Hb S, which causes severe hemolytic anemia, episodic painful vaso-occlusion, and ultimately end-organ damage. The primary disease pathophysiology is intracellular Hb S polymerization and consequent sickling of erythrocytes. It has become evident for more than several decades that a more complex disease process contributes to the myriad of clinical complications seen in patients with SCD with inflammation playing a central role. Drugs targeting specific inflammatory pathways therefore offer an attractive therapeutic strategy to ameliorate many of the clinical events in SCD. In addition, they are useful tools to dissect the molecular and cellular mechanisms that promote individual clinical events and for developing improved therapeutics to address more challenging clinical dilemmas such as refractoriness to opioids or hyperalgesia. Here, we discuss the prospect of targeting multiple inflammatory pathways implicated in the pathogenesis of SCD with a focus on new therapeutics, striving to link the actions of the anti-inflammatory agents to a defined pathobiology, and specific clinical manifestations of SCD. We also review the anti-inflammatory attributes and the cognate inflammatory targets of hydroxyurea, the only Food and Drug Administration-approved drug for SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.